LXRX

LEXICON PHARMACEUTICALS, INC.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$2.02

−$0.13−6.05%

Delayed · 2026-09-10T20:00:00.000Z · marketstack

1 of 47tracked managers hold this· Q2 2026

Aug 12, 2026$2.02

−$0.33−14.04%over 1M

Day range8% of range

$2.01$2.14

Session

Previous close: $2.15
Open: $2.11
Volume: 2.94M
Avg volume: -
Day high: $2.14
Day low: $2.01

Fundamentals

Visualize fundamentals and more

Market cap: 884.06M
P/E ratio: -
EPS (TTM): -$0.14
Dividend yield: -
Beta: 1.00
Shares outstanding: 437.65M

Source SEC EDGAR · 9/11/2026

Tracked investors

As of Q2 2026 · 74 days ago · next update ~14 Nov 2026· what moved this quarter, onMeasure

1 fund manager this platform follows disclosed a position in LXRX, from quarterly SEC filings up to 45 days old; a manager may have sold since without yet having to say so.

Joel Greenblatt
Gotham Asset Management
$32.71K
<0.01%of book

Manager	Position	Share of their book	Last change
Joel Greenblatt Gotham Asset Management	$32.71K	<0.01%

Share price, with each quarter a tracked manager’s position changed shaded across the range it traded in.

061218

now

Q1 '16

Q2 '16

Q3 '16

Q4 '16

Q1 '17

Q2 '26

Hover a shaded quarter to see it moved. Who, and the range they traded in, is onBespoke

13F filings cover US-listed shares only (not cash, bonds, shorts, or private holdings) and are never a recommendation to do the same.

Risk factors, year on year

Item 1AMarch 2026 10-KMarch 2025as filed.

added: 16
dropped: 17
re-drafted: 23

Out of 149 passages in this year’s Item 1A.

The assistant has not been given these passages. It will say so, and say what opens them. This costs you no question.

New this year

We are developing sotagliflozin for HCM and pilavapadin for neuropathic pain and are conducting research and development of compounds from a number of additional drug programs. We cannot offer any assurances or predict with any certainty that our ongoing …

32 more passages, included withBespoke

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Litigation
Reimbursement
Debt covenants
Product recalls
Going concern
Pandemic
Cybersecurity

And 12 more.

FDA approval
We cannot offer any assurances or predict with any certainty that our ongoing research and development efforts, including our SONATA-HCM Phase 3 clinical trial of sotagliflozin in HCM, will be successfully completed, generate positive data or demonstrate …

7 more themes, included withMeasure

Recent activity

16 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Companies like LEXICON PHARMACEUTICALS, INC.

Also filed under Biotechnology, ranked by how closely they sit beside LXRX.

MRNAModerna, Inc.
ALNYALNYLAM PHARMACEUTICALS, INC.
NVONOVO NORDISK A S
REGNREGENERON PHARMACEUTICALS, INC.
VRTXVERTEX PHARMACEUTICALS INC / MA
INSMINSMED Inc

Ask about LEXICON PHARMACEUTICALS, INC.

The assistant answers from what LXRX has actually filed: 17 annual reports filed with the SEC, 13F positions from the 1 tracked investor who hold it and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from LXRX's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding LEXICON PHARMACEUTICALS, INC., and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

What an account lets you do with LEXICON PHARMACEUTICALS, INC.

Separate the decisions from the paperwork
Every Form 4 LXRX insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about LEXICON PHARMACEUTICALS, INC.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free accountSee what the paid plans add

Free, no card, and it does not expire.